Gazyva: Additional Ph III GALLIUM data

Additional data from 1,202 patients with previously untreated follicular lymphoma in the open-label, international Phase III GALLIUM trial showed that induction therapy with Gazyva plus chemotherapy followed by maintenance therapy with Gazyva alone improved investigator-assessed PFS, the primary endpoint,

Read the full 398 word article

User Sign In